Introduction: Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambique's progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of people with AHD is critical to address this important condition. Methods: Data were reviewed from October to December 2023 from the 79 health facilities at a national level implementing the AHD diagnosis and treatment package at the national level. Results: Overall, 36% (7.811/21.452) of people living with HIV new initiated or reinitiated on antiviral treatment had a CD4 test, of which 1.986 were diagnosed with AHD (25%). Most of the diagnosed cases were in people living with HIV that were newly initiated (1.814) versus those being reinitiated (179). Conclusion: The low coverage of CD4 testing in eligible patients is an obstacle to the early identification of AHD patients and the reduction of mortality, and consequently a barrier to HIV elimination in Mozambique.